[go: up one dir, main page]

BRPI0506865A - inibidores de hmg-coa redutase inusitados, baseados em imidazóis - Google Patents

inibidores de hmg-coa redutase inusitados, baseados em imidazóis

Info

Publication number
BRPI0506865A
BRPI0506865A BRPI0506865-7A BRPI0506865A BRPI0506865A BR PI0506865 A BRPI0506865 A BR PI0506865A BR PI0506865 A BRPI0506865 A BR PI0506865A BR PI0506865 A BRPI0506865 A BR PI0506865A
Authority
BR
Brazil
Prior art keywords
coa reductase
reductase inhibitors
unusual
imidazole
hmg
Prior art date
Application number
BRPI0506865-7A
Other languages
English (en)
Inventor
Mark Richard Bush
Michael David Kaufman
Robert Michael Kennedy
Scott Douglas Larsen
Bharatkumar Kalidas Trivedi
Yuntao Song
Richard Henry Hutchings
Toni-Jo Poel
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Publication of BRPI0506865A publication Critical patent/BRPI0506865A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/84—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/88—Nitrogen atoms, e.g. allantoin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/90—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurosurgery (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

INIBIDORES DE HMG-COA REDUTASE INUSITADOS, BASEADOS EM IMIDAZóIS A presente invenção fornece compostos inibidores de HMG CO-A redutase, úteis como agentes hipocolesterolêmicos e hipolipidêmicos. são fornecidas também composições farmacêuticas dos compostos. Métodos para fabricar e métodos para usar os compostos também são fornecidos.
BRPI0506865-7A 2004-01-20 2005-01-10 inibidores de hmg-coa redutase inusitados, baseados em imidazóis BRPI0506865A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US53752504P 2004-01-20 2004-01-20
US62905804P 2004-11-18 2004-11-18
PCT/IB2005/000030 WO2005079790A1 (en) 2004-01-20 2005-01-10 Imidazole-based hmg-coa reductase inhibitors

Publications (1)

Publication Number Publication Date
BRPI0506865A true BRPI0506865A (pt) 2007-05-29

Family

ID=34890439

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0506865-7A BRPI0506865A (pt) 2004-01-20 2005-01-10 inibidores de hmg-coa redutase inusitados, baseados em imidazóis

Country Status (6)

Country Link
EP (1) EP1727541A1 (pt)
JP (1) JP2007518787A (pt)
BR (1) BRPI0506865A (pt)
CA (1) CA2548218A1 (pt)
MX (1) MXPA06006396A (pt)
WO (1) WO2005079790A1 (pt)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0427491D0 (en) 2004-12-16 2005-01-19 Avecia Ltd Process and compounds
US20090227602A1 (en) * 2005-10-28 2009-09-10 John Griffin Compositions and treatments for inhibiting kinase and/or hmg-coa reductase
US8071631B2 (en) 2006-08-16 2011-12-06 The J. David Gladstone Institutes, A Testamentary Trust Established Under The Will Of J. David Gladstone Small molecule inhibitors of kynurenine-3-monooxygenase
EP2054397B1 (en) 2006-08-16 2015-10-07 The J. David Gladstone Institutes, A Testamentary Trust Established under The Will of J. David Gladstone Small molecule inhibitors of kynurenine-3-monooxygenase
US8877221B2 (en) 2010-10-27 2014-11-04 Warsaw Orthopedic, Inc. Osteoconductive matrices comprising calcium phosphate particles and statins and methods of using the same
US9107983B2 (en) 2010-10-27 2015-08-18 Warsaw Orthopedic, Inc. Osteoconductive matrices comprising statins
US9308190B2 (en) 2011-06-06 2016-04-12 Warsaw Orthopedic, Inc. Methods and compositions to enhance bone growth comprising a statin
USD721807S1 (en) 2011-09-08 2015-01-27 Ams Research Corporation Surgical indicators

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4808607A (en) * 1985-05-22 1989-02-28 Sandoz Pharm. Corp. Imidazole analogs of mevalonolactone and derivatives thereof for use in inhibiting cholesterol biosynthesis and lowering blood cholesterol level
DE3817808A1 (de) * 1987-07-21 1989-02-02 Bayer Ag Verfahren zur herstellung von 2-substituierten pyrrolen
DE3739882A1 (de) * 1987-11-25 1989-06-08 Bayer Ag Substituierte hydroxylamine

Also Published As

Publication number Publication date
WO2005079790A1 (en) 2005-09-01
JP2007518787A (ja) 2007-07-12
EP1727541A1 (en) 2006-12-06
CA2548218A1 (en) 2005-09-01
MXPA06006396A (es) 2006-08-23

Similar Documents

Publication Publication Date Title
BRPI0413468A (pt) inibidores de hmg-coa redutase baseados em pirrol
TW200634018A (en) Azolopyrimidine-based inhibitors of dipeptidyl peptidase IV and uses
DK1942898T4 (da) Dipeptidylpeptidase-inhibitorer til behandling af diabetes
BRPI0509184A (pt) composições farmacêuticas
IL185275A0 (en) N-sulphonylpyrrole derivatives and pharmaceutical compositions containing the same
WO2007103366A3 (en) Hmg co-a reductase inhibitor enhancement of bone and cartilage
WO2005087724A3 (en) Sulphonylpyrroles as hdac inhibitors
BRPI0713031B8 (pt) composto de di-hidro-piran-2-ona, composição farmacêutica, e uso dos mesmos
UY31273A1 (es) Fenilendiaminas sustituidas como inhibidores de la interaccion entre mdm2 y p53
DE602007005372D1 (de) Zweischichtige tablette zur verhinderung von kardiovaskulären ereignissen
ATE544769T1 (de) 2-(substituiertes amino)- benzothiazolsulfonamidverbindungen als hiv- protease-inhibitoren
GEP20104941B (en) Pyrrolopyridine-based inhibitors of dipeptidyl peptidase iv and methods
BRPI0506865A (pt) inibidores de hmg-coa redutase inusitados, baseados em imidazóis
EA200801413A1 (ru) Гетероциклические сетр ингибиторы
CR9521A (es) Metodo novedoso de tratamiento de la hiperlipedemia
TW200738649A (en) Calcilytic compounds
CY1111768T1 (el) Νεος παραγοντας μειωσης τριγλυκεριδιου
UY28653A1 (es) N-alquil pirroles como inhibidores de la hmg-coa reductasa
BRPI0509926A (pt) imidazóis
EA200500202A1 (ru) Новый способ синтеза (7-метокси-3,4-дигидро-1-нафталинил)ацетонитрила и его применение при синтезе агомелатина
DE60234868D1 (de) Amorphe hmg-coa-reduktase-inhibitoren mit gewünschter teilchengrösse
EA200970355A1 (ru) Новый кристалл (s)-(+)-2-(2-хлорфенил)-2-гидроксиэтилкарбамата
ITMI20050477A1 (it) Cerotto transdermico
BRPI0507859A (pt) uso dos inibidores da colinesterase
ATE496025T1 (de) Magnesiumsalze von hmg-coa-reduktase-hemmern

Legal Events

Date Code Title Description
B08F Application fees: dismissal - article 86 of industrial property law

Free format text: REFERENTE A 4A,5AE 6A ANUIDADES

B08K Lapse as no evidence of payment of the annual fee has been furnished to inpi (acc. art. 87)

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2099 DE 29/03/2011.